Directorate Change

BEXIMCO PHARMACEUTICALS LTD.

12 January, 2011

Directorate Change

Beximco Pharmaceuticals Limited ("BXP" or "the Company"; AIM Symbol: BXP) today regrets to announce the death of Dr Farida Huq, a member of its Board of Directors, on 7 January 2011.

Dr Huq was formerly a Director of the Government Institute of Public Health in Bangladesh and was the Medical Director of BXP until 2006, after which she remained with the company as a Board Director. Dr Huq also served as an honorary senior consultant of the Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM).

Mr Nazmul Hassan, Managing Director of BXP, said: "Dr Huq will be missed on both a personal and professional level by her colleagues. We remain grateful for her contribution to the business over many years which has greatly influenced BXP's strategy and success. Our thoughts and condolences are now with her family and friends at this difficult time."

For further information please visit www.beximco-pharma.com or enquire to:

Beximco Pharma

Nazmul Hassan, MP

Managing Director

Tel: +880 2 861 9151, ext.2080

Md. Asad Ullah, FCS, Company Secretary

Tel; +880 2 8618220-1, Ext 1140

Libertas

Jakob Kinde / Anthony Rowland

Tel: +44 (0)20 7569 9650

Financial Dynamics

Jonathan Birt / Susan Quigley

Tel: +44 (0)20 7269 7169

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.